RxDoctor Payments Data

Julie Frankel, DO

Family Medicine · Suffolk, VANPI 1104321132

Payments from drug & device makers

$7,616in general payments, 2019–2025

Across 432 payments — averaging $17.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$885
  • Amgen$858
  • AstraZeneca$766
  • Pfizer$590
  • Lilly USA, LLC$505
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$7,55099%
  • Education$661%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,616 in reported general payments places this provider in the 90th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$162,909
Medicare patients
342
Services billed
2,071

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$142,459
JardianceEmpagliflozin54$62,902
EliquisApixaban46$52,392
FarxigaDapagliflozin Propanediol40$49,858
TrulicityDulaglutide25$42,095
MounjaroTirzepatide29$34,264
JanuviaSitagliptin Phosphate15$21,595
XareltoRivaroxaban19$17,665
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$17,251
MyrbetriqMirabegron12$16,124
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$8,405
Repatha SyringeEvolocumab13$7,048
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$6,103
Spiriva RespimatTiotropium Bromide11$5,699
Atorvastatin Calcium377$4,457

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$885$142,45982 claims
Lilly USA, LLCTrulicity, Mounjaro$505$76,35854 claims
Boehringer IngelheimJardiance, Spiriva Respimat$75$68,60165 claims
PfizerEliquis$590$52,39246 claims
AstraZenecaFarxiga$766$49,85840 claims
GSKTrelegy Ellipta, Anoro Ellipta$147$23,35426 claims
MerckJanuvia$63$21,59515 claims
Johnson & JohnsonXarelto$61$17,66519 claims
Astellas Pharma US IncMyrbetriq$211$16,12412 claims
AbbVieSynthroid$1,065$1,05340 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Suffolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →